Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NASDAQ:INVA NASDAQ:LXRX NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$24.45-3.0%$22.75$14.40▼$47.00$1.67B1.191.58 million shs1.30 million shsINVAInnoviva$19.37-0.3%$19.61$16.67▼$22.00$1.22B0.47654,719 shs623,909 shsLXRXLexicon Pharmaceuticals$1.15+3.6%$1.12$0.28▼$2.18$403.37M1.261.65 million shs1.68 million shsNVAXNovavax$7.98-3.6%$7.66$5.01▼$15.22$1.34B2.686.75 million shs7.15 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-2.98%+6.91%-2.16%+15.00%-41.28%INVAInnoviva-0.31%-5.42%-6.02%-10.70%-0.15%LXRXLexicon Pharmaceuticals+3.60%+5.50%+3.60%+71.26%-31.95%NVAXNovavax-3.62%+1.01%-9.83%+14.99%-35.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$24.45-3.0%$22.75$14.40▼$47.00$1.67B1.191.58 million shs1.30 million shsINVAInnoviva$19.37-0.3%$19.61$16.67▼$22.00$1.22B0.47654,719 shs623,909 shsLXRXLexicon Pharmaceuticals$1.15+3.6%$1.12$0.28▼$2.18$403.37M1.261.65 million shs1.68 million shsNVAXNovavax$7.98-3.6%$7.66$5.01▼$15.22$1.34B2.686.75 million shs7.15 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-2.98%+6.91%-2.16%+15.00%-41.28%INVAInnoviva-0.31%-5.42%-6.02%-10.70%-0.15%LXRXLexicon Pharmaceuticals+3.60%+5.50%+3.60%+71.26%-31.95%NVAXNovavax-3.62%+1.01%-9.83%+14.99%-35.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.78Moderate Buy$46.6790.87% UpsideINVAInnoviva 3.00Buy$42.75120.70% UpsideLXRXLexicon Pharmaceuticals 2.50Moderate Buy$3.23180.43% UpsideNVAXNovavax 2.13Hold$14.2979.02% UpsideCurrent Analyst Ratings BreakdownLatest LXRX, CLDX, INVA, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.008/20/2025CLDXCelldex TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $38.008/20/2025CLDXCelldex TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$56.00 ➝ $48.008/20/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$64.00 ➝ $62.008/20/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $42.008/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.008/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.008/11/2025INVAInnovivaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.008/7/2025LXRXLexicon PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.20 ➝ $1.907/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$10.00 ➝ $9.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M231.30N/AN/A$11.26 per share2.17INVAInnoviva$358.71M3.40$3.42 per share5.67$11.03 per share1.76LXRXLexicon Pharmaceuticals$31.08M13.45N/AN/A$0.40 per share2.88NVAXNovavax$682.16M1.90N/AN/A($3.89) per share-2.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)INVAInnoviva$23.39M$0.3162.4912.50N/A10.44%18.67%9.92%11/5/2025 (Estimated)LXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)NVAXNovavax-$187.50M$2.283.5099.750.1139.20%-142.33%28.65%11/11/2025 (Estimated)Latest LXRX, CLDX, INVA, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 million8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A19.6719.67INVAInnoviva0.362.642.44LXRXLexicon Pharmaceuticals0.434.164.16NVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AINVAInnoviva99.12%LXRXLexicon Pharmaceuticals74.70%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%INVAInnoviva2.25%LXRXLexicon Pharmaceuticals13.90%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableLXRX, CLDX, INVA, and NVAX HeadlinesRecent News About These CompaniesBayforest Capital Ltd Purchases New Stake in Novavax, Inc. $NVAX1 hour ago | marketbeat.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowSeptember 10 at 10:01 AM | zacks.comPark West Asset Management LLC Acquires New Position in Novavax, Inc. $NVAXSeptember 8, 2025 | marketbeat.comNorthern Trust Corp Reduces Position in Novavax, Inc. $NVAXSeptember 8, 2025 | marketbeat.comNovavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.comNuvaxovid® Now Approved in Japan Triggering Takeda Milestone PaymentSeptember 4, 2025 | prnewswire.comNovavax ‘applauds’ President Trump’s call for available COVID-19 vaccine dataSeptember 4, 2025 | msn.comNovavax to Participate in the Cantor Global Healthcare ConferenceSeptember 3, 2025 | finance.yahoo.comOMERS ADMINISTRATION Corp Takes $1.28 Million Position in Novavax, Inc. $NVAXSeptember 3, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Receives $14.29 Consensus PT from AnalystsSeptember 3, 2025 | americanbankingnews.comOptimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy RatingSeptember 2, 2025 | tipranks.comRafferty Asset Management LLC Sells 80,502 Shares of Novavax, Inc. $NVAXSeptember 2, 2025 | marketbeat.comInvesco Ltd. Boosts Stake in Novavax, Inc. $NVAXSeptember 2, 2025 | marketbeat.comFY2025 Earnings Forecast for Novavax Issued By HC WainwrightSeptember 2, 2025 | marketbeat.comHC Wainwright Comments on Novavax FY2025 EarningsSeptember 2, 2025 | americanbankingnews.comNuveen LLC Purchases New Position in Novavax, Inc. $NVAXSeptember 1, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 1, 2025 | marketbeat.comQ3 Earnings Forecast for Novavax Issued By HC WainwrightAugust 31, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Novavax (NASDAQ:NVAX)August 30, 2025 | marketbeat.comKohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by AnalystsAugust 30, 2025 | tipranks.comNovavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLAAugust 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX, CLDX, INVA, and NVAX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$24.45 -0.75 (-2.98%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$24.44 -0.01 (-0.04%) As of 09/12/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$19.37 -0.06 (-0.31%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$19.36 -0.01 (-0.05%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Lexicon Pharmaceuticals NASDAQ:LXRX$1.15 +0.04 (+3.60%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Novavax NASDAQ:NVAX$7.98 -0.30 (-3.62%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.98 0.00 (-0.01%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
